XOMA (XOMA) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-36.05M
Depreciation
Common shares contribution to 401(k)
Share-based compensation expense	6.2M
Accrued interest on interest bearing obligations
Revaluation of warrant liabilities
Warrant modification expense
Amortization of discount on long-term debt	1.08M
Unrealized loss on foreign currency exchange	384K
Unrealized gain on foreign exchange options
Other non-cash adjustments	79K
Receivables	3.31M
Prepaid expenses and other assets	676K
Accounts payable and accrued liabilities	-4.54M
Deferred revenue	-2.31M
Other liabilities	-500K
Net cash used in operating activities
Net purchase of property and equipment	-31K
Net cash used in investing activities
Proceeds from issuance of long-term debt	0
Proceeds from issuance of common shares	45K
Payment for modification of warrants
Net cash provided by financing activities
Effect of exchange rate changes on cash
Net increase in cash and cash equivalents	-45.15M
Cash and cash equivalents at the beginning of the period	65.77M
Cash and cash equivalents at the end of the period	20.62M
Income taxes
Discount on long-term debt
Issuance and extinguishment of warrant liabilities
Interest added to principal balance on Novartis note

Entities mentioned with XOMA

View All Entities